Financial Statements and Highlights | Takeda Investor Relations

EN

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

February 10, 2026

Takeda Reports Third-Quarter FY2025 Results – Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind – Progressing Toward Three Transformative Launches Ahead

January 29, 2026

Takeda Announces Changes to Organizational Structure and Executive Leadership Team for Fiscal Year 2026 to Fuel Speed, Competitiveness and Future Growth

January 29, 2026

Takeda to Hold Earnings Call for Fiscal Year 2025 3rd Quarter on January 29

January 15, 2026

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline